{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:43:02Z","timestamp":1791268982659,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ejca.2018.04.008","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T11:13:22Z","timestamp":1527851602000},"page":"38-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group"],"prefix":"10.1016","volume":"98","author":[{"given":"Emmanuel","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillemette","family":"Bernadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Maroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Theodore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinu","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"de Crevoisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-L\u00e9on","family":"Lagrange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Grellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Clarisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idlir","family":"Licaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Habrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Carrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.ejca.2018.04.008_bib1","doi-asserted-by":"crossref","first-page":"iii49","DOI":"10.1093\/annonc\/mdu259","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Escudier","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.04.008_bib2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.eururo.2011.06.049","article-title":"The epidemiology of renal cell carcinoma","volume":"60","author":"Ljungberg","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2018.04.008_bib3","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.3390\/cancers3044010","article-title":"Role of radiation therapy in the management of renal cell cancer","volume":"3","author":"Blanco","year":"2011","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2018.04.008_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0360-3016(95)02029-2","article-title":"A review of human cell radiosensitivity in\u00a0vitro","volume":"34","author":"Deschavanne","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2018.04.008_bib5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijrobp.2009.09.042","article-title":"American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy","volume":"76","author":"Potters","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2018.04.008_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3340\/jkns.2013.54.2.107","article-title":"The usefulness of stereotactic radiosurgery for radioresistant brain metastases","volume":"54","author":"Kim","year":"2013","journal-title":"J Korean Neurosurg Soc"},{"key":"10.1016\/j.ejca.2018.04.008_bib7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2018.04.008_bib8","doi-asserted-by":"crossref","first-page":"20160251","DOI":"10.1259\/bjr.20160251","article-title":"Stereotactic body radiotherapy for oligoprogressive cancer","volume":"89","author":"Cheung","year":"2016","journal-title":"Br J Radiol"},{"issue":"251997","key":"10.1016\/j.ejca.2018.04.008_bib9","first-page":"8","article-title":"Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in\u00a0vitro and in\u00a0vivo in human renal cell carcinoma xenografts","volume":"80","author":"Ning","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2018.04.008_bib10","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cncr.23209","article-title":"A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions","volume":"112","author":"Milano","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2018.04.008_bib11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2217\/fon.14.40","article-title":"Extracranial oligometastatic renal cell carcinoma: current management and future directions","volume":"10","author":"Loh","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2018.04.008_bib12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/0284186X.2014.939298","article-title":"Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review","volume":"54","author":"Kothari","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2018.04.008_bib13","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.ijrobp.2011.02.040","article-title":"Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma","volume":"82","author":"Zelefsky","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2018.04.008_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2005.03.022","article-title":"Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma","volume":"77","author":"Wers\u00e4ll","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2018.04.008_bib15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/02841860600954875","article-title":"A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma","volume":"45","author":"Svedman","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2018.04.008_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijrobp.2017.01.032","article-title":"Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases","volume":"98","author":"Wang","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ejca.2018.04.008_bib17","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jjco\/hyq044","article-title":"Clinical outcomes of stereotactic brain and\/or body radiotherapy for patients with oligometastatic lesions","volume":"40","author":"Inoue","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.04.008_bib18","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/COC.0b013e31825d52b2","article-title":"Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma","volume":"36","author":"Ranck","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.04.008_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fonc.2012.00155","article-title":"Observation as a treatment strategy for advanced renal cell carcinoma-a call for prospective validation","volume":"2","author":"Fisher","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2018.04.008_bib20","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00432-014-1680-9","article-title":"Active surveillance for metastatic or recurrent renal cell carcinoma","volume":"140","author":"Park","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2018.04.008_bib21","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.04.008_bib22","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2018.04.008_bib23","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.04.008_bib24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/JTO.0b013e31827e1f83","article-title":"Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors","volume":"8","author":"Yu","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2018.04.008_bib25","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/S1470-2045(13)70569-2","article-title":"Radiotherapy for renal-cell carcinoma","volume":"15","author":"De Meerleer","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.04.008_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11523-013-0280-y","article-title":"Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial","volume":"9","author":"Kao","year":"2014","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejca.2018.04.008_bib27","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1464-410X.2010.09895.x","article-title":"Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma","volume":"108","author":"Staehler","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2018.04.008_bib28","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.04.008_bib29","first-page":"18","article-title":"Immune effects of high dose radiation treatment: implications of ionizing radiation on the development of bystander and abscopal effects","volume":"3","author":"Sologuren","year":"2014","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.ejca.2018.04.008_bib30","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2326-6066.CIR-14-0138","article-title":"PD-1 restrains radiotherapy-induced abscopal effect","volume":"3","author":"Park","year":"2015","journal-title":"Cancer Immunol Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918308098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918308098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T06:50:31Z","timestamp":1720335031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918308098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":30,"alternative-id":["S0959804918308098"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.04.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}